Cryptococcosis pathophysiology

Jump to navigation Jump to search

Cryptococcosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cryptococcosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cryptococcosis pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cryptococcosis pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cryptococcosis pathophysiology

CDC on Cryptococcosis pathophysiology

Cryptococcosis pathophysiology in the news

Blogs on Cryptococcosis pathophysiology

Directions to Hospitals Treating Cryptococcosis

Risk calculators and risk factors for Cryptococcosis pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Serge Korjian M.D.; Yazan Daaboul, M.D.

Overview

Infective cryptococcal species are ubiquitous and natural exposure by inhalation is very common. Cryptococci are intracellular pathogens. Once they are phagocytosed, they germinate and multiply within the macrophages. The immune response to cryptococcal infection is highly dependent on host T-cell function, and interferon-γ and TNF-α signaling. Microscopically, cryptococci are characterized by a thick mucopolysaccharde capsule with a refractile center.

Pathophysiology

  • Infective cryptococcal species are ubiquitous and natural exposure is very common.
  • Infection occurs by inhalation of aerosolized, dessicated basidiospores.
  • Once these spores reach the alveoli, they are phagocytosed by the alveolar macrophages without prior opsonization (usually required for yeast forms).
  • Cryptococci are intracellular pathogens. Once they are phagocytosed, they germinate and multiply within the macrophages.
  • Activated macrophages are capable of destroying the yeast forms that develop; however, non-activated macrophages act as germination centers for cryptococci.
  • Cryptococci have the ability of forming giant cells that resist phagocytosis and have been hypothesized to play a role in latent infections and reactivation.
  • Cryptococci also have the ability of changing the number of sets of chromosomes during infection, this has been associated with heteroresistance to certain antifungal agents.
  • After exposure to desiccated yeast cells or spores, patients may clear infection or contain it within granulomata as a latent infection, or it may disseminate depending on host immune status or other less well understood mechanisms.
  • Disseminated disease occurs among patients with compromised cell-mediated immunity.
  • The immune response to cryptococcal infection is highly dependent on host T-cell function, and interferon-γ and TNF-α signaling.
  • Granuloma formation can also be seen and may also be responsible for reactivation in patients with immunocompromised states.[1][2]

Microscopic Pathology

Cryptococcosis of the lung in patient with AIDS (Mucicarmine stain)
Cryptococcosis in the cerebrospinal fluid with light India ink staining


  • Cryptococcus exists in yeast form.
  • It is round/ovoid and approximately 5-15 μm (resembles Histoplasma or Candida, but often larger).
  • It is characterized by a thick mucopolysaccharde capsule with a refractile center.
  • India ink staining is used for easy visualization of the capsule in cerebrospinal fluid.[3]
  • It has a tear drop-shaped budding pattern which is useful in differentiating Cryptococcus from Blastomyces and Histoplasma.
  • Cryptococcal infections are usually accompanied by very little inflammation.
  • Cryptococcus stain positive with methenamine silver, Alcian blue, and PAS (may be confused with corpora amylacea in the CNS).[4]


Cryptococcosis (PAS stain)

{{#ev:youtube|ZG0AcmtBLe4}}

References

  1. Brizendine KD, Baddley JW, Pappas PG (2011). "Pulmonary cryptococcosis". Semin Respir Crit Care Med. 32 (6): 727–34. doi:10.1055/s-0031-1295720. PMID 22167400.
  2. May RC, Stone NR, Wiesner DL, Bicanic T, Nielsen K (2015). "Cryptococcus: from environmental saprophyte to global pathogen". Nat Rev Microbiol. doi:10.1038/nrmicro.2015.6. PMID 26685750.
  3. Zerpa R, Huicho L, Guillén A (1996). "Modified India ink preparation for Cryptococcus neoformans in cerebrospinal fluid specimens". J Clin Microbiol. 34 (9): 2290–1. PMC 229234. PMID 8862601.
  4. Fungi. Libre Pathology (2015). http://librepathology.org/wiki/index.php/Fungi#Cryptococcosis. Accessed on December 31, 2015.